Project Grant R01CA291918
Award Date
4/11/25
Completion Date
3/31/30
Dollars Obligated
$543K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Texas A&M University aims to develop more potent, stable, and selective small molecule and peptidic inhibitors and proteolysis targeting chimeras (PROTACs) that target the ENL protein, which is a key player in acute myeloid leukemia (AML). The $476,558 award, spanning from June 1, 2024 to May 31, 2029, supports a multi-pronged approach to identify and optimize these...
This federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $768,437 to the Sanford Burnham Prebys Medical Discovery Institute to conduct research aimed at identifying chemical compounds that can inhibit the chromatin reader protein SGF29. This target has been identified as a potent regulator of oncogenic transcription factors in acute myeloid leukemia (AML), a devastating disease with limited treatment options. The research will...
This Project Grant award from the National Cancer Institute under the Cancer Biology Research (CFDA 93.396) program will support research at Case Western Reserve University to investigate a novel approach to treat acute myeloid leukemia (AML). The $491,357 award, granted on March 15, 2025, aims to establish a mechanistic understanding of how hyperactivation of the mTOR pathway can be leveraged to enhance the efficacy of proteasome inhibitors in killing AML cells. The research will map the...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to identify novel gene drivers that contribute to therapy resistance and disease relapse in acute myeloid leukemia (AML). The $458,698 award to the Regents of the University of Michigan, effective March 10, 2025, will fund a 5-year project to study genes that confer growth advantages to leukemia cells and enable AML relapse despite initial treatment response. The research aims to...
This federal Project Grant award of $2,775,137, provided by the National Cancer Institute (NCI) under the Cancer Biology Research (CFDA 93.396) program, supports comprehensive research to understand the aging-related mechanisms that contribute to the progression of acute myeloid leukemia (AML) from pre-AML conditions like age-related clonal hematopoiesis (ARCH) and myelodysplastic syndromes (MDS). The award supports an integrated research program that utilizes cutting-edge genetic tools,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $686,937 to The University of Texas Southwestern Medical Center to support research focused on uncovering therapeutic vulnerabilities in acute myeloid leukemia (AML) through mechanistic interrogation of MECOM activity. The research aims to 1) define essential co-regulators and direct targets of MECOM, a transcription factor that is essential for AML maintenance, and 2)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to identify and characterize different leukemia initiating cell (LIC) subtypes and their vulnerabilities in acute myeloid leukemia (AML) in order to develop more effective and durable therapies. The $387,630 award, which spans from July 2024 to June 2029, will fund studies to mechanistically understand how inhibiting inhibitor of apoptosis proteins (IAP) using SMAC...
The National Cancer Institute (NCI) awarded a $734,435 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope to conduct research aimed at overcoming resistance to BH3 mimetic drugs in acute myeloid leukemia (AML). The key objectives are to: 1) determine how increased AMP synthesis via the ADSS2 enzyme promotes resistance to BH3 mimetics in AML, 2) define how ADSS2-mediated AMPK activation antagonizes BH3 mimetic-induced apoptosis, and 3)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $415,259 to the University of Virginia to study the role of long noncoding RNAs in acute myeloid leukemia (AML), a highly fatal blood cancer. The key objectives are to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. The research aims to provide insight into the functions of enhancer...
This $487,542 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by the Beckman Research Institute of the City of Hope to investigate the role of mitochondrial RNA methylation in high-risk acute myeloid leukemia (AML). The project aims to determine the functional importance of the mitochondrial methyltransferase METTL17 in AML pathogenesis, elucidate the molecular mechanisms by which METTL17 promotes leukemogenesis, and evaluate the...